Merus Labs International Inc (TSE:MSL) (NASDAQ:MSLI) has received an average recommendation of “Hold” from the seven ratings firms that are presently covering the firm. Three analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is C$1.99.

A number of analysts recently issued reports on MSL shares. CIBC increased their target price on Merus Labs International from C$1.40 to C$1.65 in a research note on Monday, May 15th. TD Securities reissued a “buy” rating and set a C$3.00 target price on shares of Merus Labs International in a research note on Wednesday, February 15th. Bloom Burton reissued a “hold” rating on shares of Merus Labs International in a research note on Monday, February 13th. Finally, Scotiabank reissued a “sector perform” rating and set a C$1.25 target price on shares of Merus Labs International in a research note on Monday, February 13th.

Shares of Merus Labs International (TSE:MSL) remained flat at $1.61 on Tuesday. The stock had a trading volume of 330,394 shares. The stock has a 50-day moving average price of $1.20 and a 200-day moving average price of $1.17. Merus Labs International has a 12 month low of $0.95 and a 12 month high of $1.83. The firm’s market cap is $188.70 million.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/05/23/merus-labs-international-inc-msl-given-consensus-recommendation-of-hold-by-brokerages.html.

About Merus Labs International

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.

12 Month Chart for TSE:MSL

Receive News & Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related companies with MarketBeat.com's FREE daily email newsletter.